Cargando…

Additional Drug Resistance Patterns among Multidrug-Resistant Tuberculosis Patients in Korea: Implications for Regimen Design

Detailed information on additional drug resistance patterns of multidrug-resistant tuberculosis (MDR-TB) is essential to build an effective treatment regimen; however, such data are scarce in Korea. We retrospectively analyzed the results of phenotypic drug susceptibility testing (DST) of culture co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mok, Jeong Ha, Kang, Bo Hyoung, Lee, Taehoon, Lee, Hyun-Kyung, Jang, Hang Jea, Cho, Yu Ji, Jeon, Doosoo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Academy of Medical Sciences 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5334162/ https://www.ncbi.nlm.nih.gov/pubmed/28244290 http://dx.doi.org/10.3346/jkms.2017.32.4.636

Ejemplares similares

Trend of multidrug and fluoroquinolone resistance in Mycobacterium tuberculosis isolates from 2010 to 2014 in Korea: a multicenter study
por: Kim, Hyeonseok, et al.
Publicado: (2019)

Additional Drug Resistance in Patients with Multidrug-resistant Tuberculosis in Korea: a Multicenter Study from 2010 to 2019
por: Lee, Taehoon, et al.
Publicado: (2021)

WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update: Applicability in South Korea
por: Jeon, Doosoo
Publicado: (2017)

Nationwide Treatment Outcomes of Patients With Multidrug/Rifampin-Resistant Tuberculosis in Korea, 2011–2017: A Retrospective Cohort Study (Korean TB-POST)
por: Choi, Hongjo, et al.
Publicado: (2023)

Cost-Effectiveness of All-Oral Regimens for the Treatment of Multidrug-Resistant Tuberculosis in Korea: Comparison With Conventional Injectable-Containing Regimens
por: Park, Hae-Young, et al.
Publicado: (2023)

Retreatment after loss to follow-up reduces mortality in patients with multidrug/rifampicin-resistant tuberculosis
por: Choi, Hongjo, et al.
Publicado: (2023)

Medical Management of Drug-Resistant Tuberculosis
por: Jeon, Doosoo
Publicado: (2015)

Impact of Anti-Tuberculosis Drug Use on Treatment Outcomes in Patients with Pulmonary Fluoroquinolone-Resistant Multidrug-Resistant Tuberculosis: A Nationwide Retrospective Cohort Study with Propensity Score Matching
por: Choi, Hongjo, et al.
Publicado: (2023)

Impact of Molecular Drug Susceptibility Testing on the Time to Multidrug-resistant Tuberculosis Treatment Initiation
por: Jeon, Doosoo, et al.
Publicado: (2020)

Time to appropriate treatment in patients with multidrug-resistant tuberculosis in South Korea: Are we still in 2010?
por: Jo, Eun-Jung, et al.
Publicado: (2019)

Improved outcomes following addition of bedaquiline and clofazimine to a treatment regimen for multidrug-resistant tuberculosis
por: Yao, Ge, et al.
Publicado: (2023)

Latent tuberculosis infection: recent progress and challenges in South Korea
por: Jeon, Doosoo
Publicado: (2020)

Treatment outcome of standardized regimen in patients with multidrug resistant tuberculosis
por: Jain, Kalpesh, et al.
Publicado: (2014)

The Growing Problem of Multidrug-Resistant Tuberculosis in North Korea
por: Seung, Kwonjune J., et al.
Publicado: (2013)

Additional Drug Resistance of Multidrug-Resistant Tuberculosis in Patients in 9 Countries
por: Kurbatova, Ekaterina V., et al.
Publicado: (2015)

Aggressive Regimens for Multidrug-Resistant Tuberculosis Decrease All-Cause Mortality
por: Mitnick, Carole D., et al.
Publicado: (2013)

Time to Culture Conversion and Regimen Composition in Multidrug-Resistant Tuberculosis Treatment
por: Tierney, Dylan B., et al.
Publicado: (2014)

Short-Course Regimen for Multidrug-Resistant Tuberculosis: A Decade of Evidence
por: Trébucq, Arnaud, et al.
Publicado: (2019)

Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives
por: Pontali, Emanuele, et al.
Publicado: (2019)

Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea
por: Yang, Jeong Seong, et al.
Publicado: (2018)

Quantitative Drug-Susceptibility in Patients Treated for Multidrug-Resistant Tuberculosis in Bangladesh: Implications for Regimen Choice
por: Heysell, Scott K., et al.
Publicado: (2015)

Side effects associated with the treatment of multidrug-resistant tuberculosis at a tuberculosis referral hospital in South Korea: A retrospective study
por: Yang, Tae Won, et al.
Publicado: (2017)

Fluoroquinolone resistance in multidrug-resistant tuberculosis patients
por: Lee, Hyun-Woo, et al.
Publicado: (2019)

Drug Resistance Patterns of Multidrug- and Extensively Drug-Resistant Tuberculosis in Korea: Amplification of Resistance to Oral Second-line Drugs
por: Kim, Chang-Ki, et al.
Publicado: (2017)

Multidrug-Resistant Tuberculosis in Child Successfully Treated with 9-Month Drug Regimen
por: Achar, Jay, et al.
Publicado: (2015)

Shorter & cheaper regimen to treat multidrug-resistant tuberculosis: A new hope
por: Prasad, Rajendra, et al.
Publicado: (2017)

What’s Next for the Standard Short-Course Regimen for Treatment of Multidrug-Resistant Tuberculosis
por: Campbell, Jonathon R., et al.
Publicado: (2019)

Outcomes with a shorter multidrug-resistant tuberculosis regimen from Karakalpakstan, Uzbekistan
por: du Cros, Philipp, et al.
Publicado: (2021)

A prospective patient registry to monitor safety, effectiveness, and utilisation of bedaquiline in patients with multidrug-resistant tuberculosis in South Korea
por: Shim, Tae Sun, et al.
Publicado: (2023)

Diagnosis and treatment of multidrug-resistant tuberculosis
por: Jang, Jong Geol, et al.
Publicado: (2020)

Multidrug-Resistant Tuberculosis Treatment in North Korea: Is Scale-Up Possible?
por: Seung, Kwonjune J., et al.
Publicado: (2016)

Multidrug-resistant tuberculosis
por: Zager, Ellen M, et al.
Publicado: (2008)

Multidrug-resistant tuberculosis
por: Lemos, Antônio Carlos Moreira, et al.
Publicado: (2013)

Multidrug-resistant Pulmonary Tuberculosis Among Young Korean Soldiers in a Communal Setting
por: Lee, Sei Won, et al.
Publicado: (2009)

Possible impact of the standardized Category IV regimen on multidrug-resistant tuberculosis patients in Mumbai
por: Udwadia, Zarir F, et al.
Publicado: (2016)

Cost-Effectiveness of Adding Bedaquiline to Drug Regimens for the Treatment of Multidrug-Resistant Tuberculosis in the UK
por: Wolfson, Lara J., et al.
Publicado: (2015)

Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China
por: Xia, Hui, et al.
Publicado: (2020)

Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in China: focus on the safety
por: Gao, Jing-Tao, et al.
Publicado: (2021)

Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis
por: Hatami, Hossein, et al.
Publicado: (2022)

Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis
por: Nasiri, Mohammad Javad, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9u6gjah4kgk883upmmiqikqah7